Recently, the insulin icodec injection (trade name: 诺和期/Awiqli) of Novo Nordisk A/S is approved for marketing by China NMPA. It is indicated for the treatment of adults with type 2 diabetes.

As a novel long-acting insulin analog, insulin icodec can reversibly bind to albumin, form a reservoir in the circulatory system and release slowly and continuously. The hypoglycemic effect of insulin icodec was evenly distributed over a one-week administration interval, and the duration of the hypoglycemic effect could be covered over a one-week period at clinically relevant dosage.

The marketing of this drug provides a new treatment option for adult patients with type 2 diabetes.